Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
在既往未接受过DMARD治疗且预后不良的早期活动性类风湿关节炎患者中,塞妥珠单抗聚乙二醇联合剂量优化的甲氨蝶呤:一项随机、双盲、安慰剂对照的III期研究的1年结果
期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2015-209057
Emery, P; Bingham, C O 3rd; Burmester, G R; Bykerk, V P; Furst, D E; Mariette, X; van der Heijde, D; van Vollenhoven, R; Arendt, C; Mountian, I; Purcaru, O; Tatla, D; VanLunen, B; Weinblatt, M E